Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical, Inc. (ISRG) is a medical technology company headquartered in Sunnyvale, California and known for its role in minimally invasive care and robotic-assisted surgery. Its news flow frequently centers on developments related to the da Vinci surgical systems and the Ion endoluminal system, along with financial performance updates and regulatory milestones.
Investors and healthcare professionals following ISRG news can expect regular earnings announcements, where the company reports quarterly and preliminary annual financial results. These updates typically highlight worldwide procedure growth on da Vinci and Ion platforms, changes in the installed base of systems, and trends in systems, instruments, and accessories revenue.
Another major category of Intuitive news involves product clearances and platform enhancements. Recent press releases describe FDA clearances expanding indications for the da Vinci Single Port (SP) system to additional general surgery procedures, clearance of advanced energy instruments such as Vessel Sealer Curved, and regulatory certifications for the da Vinci 5 system in regions including the European Union and Japan. News also covers software and digital features for da Vinci 5, such as Force Gauge, In-Console Video Replay, and Network CCM for remote software updates.
Intuitive’s news feed also includes updates on the Ion endoluminal system, including FDA-cleared software releases that introduce artificial intelligence across Ion’s navigational workflow and integrate advanced imaging capabilities to support lung biopsy procedures. Additional stories describe demonstrations of telesurgery capabilities using da Vinci 5 and collaborations with hospitals adopting newer platforms.
For those tracking ISRG, this news page provides a consolidated view of company press releases, allowing readers to monitor procedure and system trends, regulatory progress, and technology updates that shape Intuitive’s position in robotic-assisted surgery and minimally invasive care.
Neptune Medical, a medical device innovator, has announced a successful $97 million Series D financing and the spinout of its subsidiary, Jupiter Endovascular. The financing round saw significant participation from Sonder Capital and Olympus of the Americas, along with other existing and new investors. This strategic move allows Neptune Medical to focus on gastrointestinal robotics, while Jupiter Endovascular will concentrate on its novel endovascular technology platform.
The financing will strengthen Neptune Medical's position in the GI space, as evidenced by the recent appointment of Dr. Fred Moll, a medical robotics pioneer, as Chairman of the Board. Both companies aim to lead innovation in their respective specialties, with Neptune pushing boundaries in GI robotics and Jupiter revolutionizing endovascular therapies.
Intuitive (NASDAQ:ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has appointed its President David J. Rosa to the company's Board of Directors, effective July 24, 2024. Rosa joins CEO Gary S. Guthart as one of two Intuitive executives on the Board. With nearly 27 years at Intuitive, Rosa has held leadership positions across multiple functions and currently oversees the company's business unit, quality, regulatory, manufacturing, and commercial operations.
Rosa's appointment expands the Board from eleven to twelve directors, adding his deep operational experience to complement Guthart's focus on enterprise strategy. This move aims to balance strategy and operations at the Board level, enhancing Intuitive's stewardship.
Intuitive (Nasdaq: ISRG) reported strong Q2 2024 financial results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew approximately 17% compared to Q2 2023. The company placed 341 da Vinci surgical systems, including 70 da Vinci 5 systems, bringing the total installed base to 9,203 systems, a 14% increase year-over-year.
GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, while non-GAAP net income was $641 million, or $1.78 per diluted share. Instruments and accessories revenue increased by 16% to $1.24 billion, driven by procedure volume growth. The company ended Q2 with $7.68 billion in cash, cash equivalents, and investments.
Intuitive (NASDAQ: ISRG) announced FDA clearance for revised labeling of its da Vinci X and Xi systems, specific to radical prostatectomy. The revision is based on real-world evidence from 2007 to 2014, indicating similar five- to 10-year cancer survival rates for robotic-assisted and open surgeries. This collaboration involved the FDA, Aetion, and NEST, highlighting the potential of real-world data in regulatory science. The labeling change reflects these findings, affirming the non-inferiority of robotic-assisted surgeries in cancer treatment outcomes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.